Mouse models in coagulation

Thrombosis and Haemostasis

Volumn 87, Issue 4, 2002, Pages 563-574

  Hogan, Kelly A ^a   Weiler, Harmut ^a   Lord, Susan T ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Gene targeting; Hemostasis; Mice; Thrombosis; Vasculogenesis

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN III; APOLIPOPROTEIN E; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; FATTY ACID BINDING PROTEIN; FIBRIN; FIBRINOGEN; PADGEM PROTEIN; PLASMIN; PLASMINOGEN ACTIVATOR; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2; PROTHROMBIN; THROMBIN; THROMBOMODULIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; TRANSCRIPTION FACTOR NF E2; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ANGIOGENESIS; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; EMBRYO DEVELOPMENT; EXPERIMENTAL MODEL; GENE MUTATION; GENE TARGETING; HEMOSTASIS; MORPHOGENESIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; THROMBOCYTE; THROMBOPHILIA; THROMBOSIS;

EID: 0036217996     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613050     Document Type: Review

References (123)

1. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin
2. Fatal embryonic bleeding events in mice lacking tissue factor, the cell-associated initiator of blood coagulation
3. Role of tissue factor in embryonic blood vessel development
4. Targeted disruption of the murine tissue factor gene results in embryonic lethality
5. Low levels of tissue factor are compatible with development and hemostasis in mice
6. Tissue factor - A receptor involved in the control of cellular properties, including angiogenesis
7. Tissue factor signaling
8. Mouse embryogenesis requires the tissue factor extracellular domain but not the cytoplasmic domain
9. Diverse functions of protease receptor tissue factor in inflammation and metastasis
10. Regulation of the tissue factor gene
11. A role for tissue factor in cell adhesion and migration mediated by interaction with actin-binding protein 280
12. Mice lacking factor VII develop normally but suffer fatal perinatal bleeding
13. Rescue of fatal neonatal hemorrhage in factor V deficient mice by low level transgene expression
14. Tissue factor expression during human and mouse development
15. Inherited factor VII deficiency: Molecular genetics and pathophysiology
16. Blood coagulation factor X deficiency causes partial embryonic lethality and fatal neonatal bleeding in mice
17. Fatal haemorrhage and incomplete block to embryogenesis in mice lacking coagulation factor V
18. Prothrombin deficiency results in embryonic and neonatal lethality in mice
19. Incomplete embryonic lethality and fatal neonatal hemorrhage caused by prothrombin deficiency in mice
20. Early embryonic expression of murine coagulation system components
21. A coagulation factor IX-deficient mouse model for human hemophilia B
22. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A
23. Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies
24. FIX
25. Correction of the coagulation defect in hemophilia A mice through factor VIII expression in skin
26. Human factor IX corrects the bleeding diathesis of mice with hemophilia B
27. Gene therapy for hemophilia
28. Blood coagulation factors in human embryonic-fetal development: Preferential expression of the FVII/tissue factor pathway
29. A murine model of factor XI deficiency
30. A comparison of murine and human factor XI
31. Inherited disorders of blood coagulation
32. Role of blood coagulation factor XI in downregulation of fibrinolysis
33. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis
34. High levels of coagulation factor XI as a risk factor for venous thrombosis
35. Inherited disorders of prothrombin conversion
36. Prothrombin
37. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice
38. A total fibrinogen deficiency is compatible with the development of pulmonary fibrosis in mice
39. Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/MGDF in megakaryocyte development
40. How the protease thrombin talks to cells
41. Role of the thrombin receptor in development and evidence for a second receptor
42. A role for thrombin receptor signaling in endothelial cells during embryonic development
43. Thrombin signalling and protease-activated receptors
44. Disparate temporal expression of the prothrombin and thrombin receptor genes during mouse development
45. Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa
46. Vascular endothelial growth factor production by fibroblasts in response to factor VIIa binding to tissue factor involves thrombin and factor Xa
47. Synergistic induction of endothelial tissue factor by tumor necrosis factor and vascular endothelial growth factor: Functional analysis of the tumor necrosis factor receptors
48. Vascular permeability factor: A tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration
49. Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: Conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation
50. Tissue factor, osteopontin, alphavbeta3 integrin expression in microvasculature of gliomas associated with vascular endothelial growth factor expression
51. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor
52. Tissue factor controls the balance of angiogenic and anti-angiogenic properties of tumor cells in mice
53. On the mechanism of thrombin-induced angiogenesis. Potentiation of vascular endothelial growth factor activity on endothelial cells by up-regulation of its receptors
54. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen
55. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction
56. Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice
57. Gene targeting in hemostasis. Plasminogen
58. Impaired arterial neointima formation in mice with disruption of the plasminogen gene
59. Impaired wound healing in mice with a disrupted plasminogen gene
60. Ligneous conjunctivitis in plasminogen-deficient mice
61. Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency
62. Plasminogen deficiency leads to impaired remodeling after a toxic injury to the liver
63. Impaired platelet aggregation and sustained bleeding in mice lacking the fibrinogen motif bound by integrin alpha IIb beta 3
64. Synthesis of a mouse model of the dysfibrinogen Vlissingen/Frankfurt IV
65. A novel transgenic mouse model of hyperfibrinogenemia
66. A mouse model of severe von Willebrand disease: Defects in hemostasis and thrombosis
67. Defects in hemostasis in P-selectin-deficient mice
68. Platelets roll on stimulated endothelium in vivo: An interaction mediated by endothelial P-selectin
69. The glycoprotein Ib-IX-V complex is a platelet counterreceptor for P-selectin
70. Defect in regulated secretion of P-selectin affects leukocyte recruitment in von Willebrand factor-deficient mice
71. Localized reduction of atherosclerosis in von Willebrand factor-deficient mice
72. Missense mutations in the human β fibrinogen gene cause congenital afibrinogenemia by impairing fibrinogen secretion
73. Deletion of the fibrinogen alpha-chain gene (FGA) causes congenital afibrinogenemia
74. Bleeding and thrombosis in 55 patients with inherited afibrinogenaemia
75. Structure and function of von Willebrand Factor
76. Multiple pulmonary emboli in a patient with afibrinogenaemia
77. Fatal pulmonary embolus in congenital fibropenia. Report of two cases
78. Beta3-integrin deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival
79. Increased thrombogenesis and embolus formation in mice lacking glycoprotein V
80. Taking the hype out of hyperfibrinogenemia
81. Fibrinogen deficiency is compatible with the development of atherosclerosis in mice
82. Fibrinogen deficiency reduces vascular accumulation of apolipoprotein (a) and development of atherosclerosis in apolipoprotein (a) transgenic mice
83. Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice
84. Consequences of tissue factor pathway inhibitor gene-disruption in mice
85. Factor VII deficiency rescues the intrauterine lethality in mice associated with a tissue factor pathway inhibitor deficit
86. Absence of the blood-clotting regulator thrombomodulin causes embryonic lethality in mice before development of a functional cardiovascular system
87. Thrombomodulin gene disruption and mutation in mice
88. Structure-function analyses of thrombomodulin by gene-targeting in mice: The cytoplasmic domain is not required for normal fetal development
89. Tissue-restricted expression of thrombomodulin in the placenta rescues thrombomodulin-deficient mice from early lethality and reveals a secondary developmental block
90. A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state
91. Characterization of a mouse model for thrombomodulin deficiency
92. Endothelium-specific loss of murine thrombomodulin disrupts the protein C anticoagulant pathway and causes juvenile-onset thrombosis
93. Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulapathy in mice
94. Combined factor VII/protein C deficiency results in intrauterine coagulopathy in mice
95. The characterization of mice with a targeted combined deficiency of protein C and factor XI
96. Mutation in blood coagulation factor V associated with resistance to activated protein C
97. The Leiden Thrombophilia Study (LETS)
98. Spontaneous thrombosis in mice carrying the factor V Leiden mutation
99. Complete antithrombin deficiency in mice results in embryonic lethality
100. Prothrombotic phenotype of protein Z deficiency
101. Protein-Z and thrombosis
102. Frequency of protein Z deficiency in patients with ischaemic stroke
103. Dysfunctional protein C deficiency (type II). A report of 11 cases in 3 American families and review of the literature
104. Protein C and S deficiency
105. The first mutation identified in the thrombomodulin gene in a 45-year-old man presenting with thromboembolic disease
106. Thrombomodulin gene defects in families with thromboembolic disease - A report on four families
107. Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: A case-cohort study
108. A novel thrombomodulin gene mutation in a patient suffering from sagittal sinus thrombosis
109. Identification and characterization of a thrombomodulin gene mutation coding for an elongated protein with reduced expression in a kindred with myocardial infarction
110. A murine model of myocardial microvascular thrombosis
111. Mechanisms of disease: Vascular-bed-specific hemostasis and hypercoagulable states
112. Tissue factor is required for uterine hemostasis and maintenance of the placental labyrinth during gestation
113. Hemostasis in the mouse (mus musculus): A review
114. Gene targeting in hemostasis. Tissue factor
115. Gene targeting in hemostasis. Factor VII
116. Gene targeting in hemostasis. Prothrombin
117. Gene targeting in hemostasis. FXI
118. Wound-healing defects in mice lacking fibrinogen
119. Genetic interactions between the coagulation and fibrinolytic system
120. Low levels of heparin-releaseable tissue factor pathway inhibitor in young patients with thrombosis
121. Gene targeting in hemostasis. Tissue factor pathway inhibitor
122. Antithrombin III and Heparin Cofactor II